Al Beardsley

Al has spent over 30 years working “for the patients” in drug development and company-building, and has served as Cirius’ President & CEO since 2024. Prior to Cirius, he served in various roles, including most recently as Executive Chair and COO of Galera Therapeutics [GRTX] 2010 to 2024. Al was CEO at Metabolic Solutions Development Company from 2009 until 2010, and at Kereos from 2003 until 2009, and acting CEO at Metaphore Pharmaceuticals in 2002. He has also served in various roles at Confluence Life Sciences, bioStrategies Group and Vector Securities International. Al serves or has served on a number of other public and private boards including Arbutus Biopharma [ABUS], Metallomix, Euclises, Epigenetx, KemPharm [KPHM], CollaGenex Pharmaceuticals [CGPI] and Bioseek. He received his Ph.D. in Biochemical Engineering and B.S. in Chemical Engineering from the University of Iowa and an M.B.A. in Finance from the University of Chicago.